Navigation Links
MEI Pharma Announces Pricing of Public Offering of Common Stock
Date:10/25/2013

calling (415) 364-2500, or from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by calling (631) 274-2806, or by faxing (631) 254-7140. An electronic copy of the prospectus supplement and accompanying base prospectus relating to the offering will also be available on the website of the SEC at www.sec.gov.

This release does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor being developed for advanced hematologic diseases, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The Company initiated a randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza (azacitidine) in patients with previously untreated MDS in June 2013. An open-label Phase II trial of Pracinostat in combination with Vidaza in elderly patients with AML who are unsuitable for intensive chemotherapy is expected to initiate in the fall of 2013. MEI Pharma is also developing ME-344, a mitochondrial inhibitor derived from its isoflavone-based technology platform. Results from a first-in-human, single-agent clinical study of ME-344 in patients with refractory solid tumors were presented in October 2013. In September 2013, the Company further expanded its pipeline of drug candidates with
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 BiologicTx ® today announced ... 3-way Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary ... July 9 at the Miami Transplant Institute, located at ... Kidney Paired Donation (KPD) is ... for kidney transplant with one another due to incompatible ...
(Date:7/22/2014)...  A central New York ... Total Artificial Heart implant is home, discharged from ... Freedom® portable driver to wait for a matching ... from a Syracuse architectural hardware company, suffered from ... medications, an implantable defibrillator and a pacemaker. ...
(Date:7/22/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today ... patients in its ongoing Phase 2 trial (Study 202) ... revised clinical protocol agreed to with the FDA in ... proprietary recombinant human hyaluronidase under development for the systemic ... "Our diligent effort to rapidly re-initiate patient enrollment and ...
Breaking Medicine Technology:BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... RIDGEFIELD, Conn., Oct. 24, 2011 Apelon, ... data interoperability solutions, today announced the availability ... solution. TermManager, a code set management and ... interoperability initiatives by enabling widespread access to ...
... Codexis, Inc. (Nasdaq: CDXS ) ... Codex® Screening Kits are in use or evaluation ... worldwide.  The announcement was made at CPhI  Worldwide, ... week.   Codex® Screening Kits were ...
Cached Medicine Technology:Apelon Announces Availability of New TermManager® Software 250 Pharma Companies Worldwide Now Use Codexis In Process Development 2
(Date:7/22/2014)... invasive hysterectomy using electric power morcellation, uterine cancers were ... of the procedure, according to a study published by ... procedure, in which the uterus is fragmented into smaller ... , Despite the commercial availability of electric power morcellators ... malignancy at the time of electric power morcellation (in ...
(Date:7/22/2014)... 2014) -- The American Society of Hematology (ASH) will ... Coulter Award for Lifetime Achievement in Hematology, to Kanti ... Jewish (LIJ) School of Medicine for his 50-year career ... and mentoring, and exceptional patient care. , The ... is bestowed on an individual who has been a ...
(Date:7/22/2014)... may share certain pathogenic mechanisms with cancer, according to ... Linda Kusner, Ph.D. , published in PLOS ... work shows that the very same inhibitors of apoptosis, ... cells that produce autoimmune diseases. Henry Kaminski, M.D. ... GW School of Medicine and Health Sciences (SMHS), as ...
(Date:7/22/2014)... 2014 Ticket Down is a reliable ... at Fedex Field in Landover, MD. There has never been ... of international soccer. After the success of the American national soccer ... alive and well. One way that fans of the world’s sport ... with the 2014 Guinness International Champions Cup. The tournament will kick ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) ... owing to novel medical indications created and due to ... societies where physical appearance is extremely valued. Although the ... competitors, new companies and technologies are setting ground for ... put the price of 1st-gen products under pressure, only ...
Breaking Medicine News(10 mins):Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... possibilities for more accurately determining the composition of ... two techniques that were previously considered to be ... the detection technique mass spectroscopy (MS). He has ... control mechanism for the active ingredient and excipients ...
... Oct. 24 The Certification of Disability,Management Specialists ... Center (UPMC) as the recipient of its 2007 ... programs,to promote the health and productivity of its ... the National Business Group on,Health,s 2007 Joint Forum ...
... LOS ANGELES and LAIYANG, China, Oct. 24 ... Board: GTEC) (to be known as,Genesis Pharmaceutical ... pharmaceutical company in the People,s Republic of ... CCG Elite to design and execute its,investor ...
... While some targeted therapies drugs developed to attack ... cancer cells work well by themselves, increasingly researchers ... other targeted and conventional therapies. , Reported today ... Cancer Therapeutics, multiple-target applications of new and existing drugs ...
... of Cardiovascular Disease Risk, TORONTO, Oct. 24 ... Amex: PME) today announced that clinical data and,preliminary ... the product as,a cost-effective and valuable cardiovascular risk ... the second product in the PREVU(x),line of skin ...
... Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY) announced that ... the U.K. Medicines and Healthcare products Regulatory Agency ... begin a clinical trial using intravenous administration of ... as well as immune modulator, in patients with ...
Cached Medicine News:Health News:New technique improves purity of medicines 2Health News:UPMC and UPMC Health Plan Recognized Nationally for Quality Leadership in Employee Health and Productivity 2Health News:UPMC and UPMC Health Plan Recognized Nationally for Quality Leadership in Employee Health and Productivity 3Health News:Genesis Technology Group Retains CCG Elite 2Health News:Genesis Technology Group Retains CCG Elite 3Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product 2Health News:PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product 3
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: